Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 766
- Registration Number
- NCT05891093
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 81
- Registration Number
- NCT05837455
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 16989
- Registration Number
- NCT05635357
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Georgios Papadakis
- Target Recruit Count
- 150
- Registration Number
- NCT05586802
- Locations
- 🇨🇭
Service of Endocrinology, Diabetes & Metabolism, Lausanne, Switzerland
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05549505
- Locations
- 🇪🇸
Clinical Trial Site, Zaragoza, Spain
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT05524584
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6000
- Registration Number
- NCT05514054
- Locations
- 🇺🇸
Summit Cancer Care, PC, Savannah, Georgia, United States
🇺🇸Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸Staten Island University Hospital, Staten Island, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.